Education
About Us
Working with TipRanks
Follow Us
VISEN Pharmaceuticals (HK:2561)
:2561
2561 Stock Chart & Stats
HK$41.16
--
Market closed
HK$41.16
--
Day’s Range― - ―
52-Week RangeHK$38.00 - HK$69.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)43.78K
Market Cap
HK$4.33B
Enterprise ValueHK$3.88B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding113,926,865
10 Day Avg. Volume55,350
30 Day Avg. Volume43,783
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)25.08
Price to Sales (P/S)2178.79
P/FCF Ratio-42.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$38.00 and its highest was HK$69.15 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$4.33B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
VISEN Pharmaceuticals’s upcoming earnings report date is Aug 27, 2025 which is 69 days ago.
How were VISEN Pharmaceuticals’s earnings last quarter?
VISEN Pharmaceuticals released its earnings results on Mar 27, 2025. The company reported -HK$0.609 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.609.
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
VISEN Pharmaceuticals reported an EPS of -HK$0.609 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.913%.
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Broncus Holding Corp.
―
Sinohealth Holdings Ltd.
―
SinoMab Bioscience Ltd.
―
Town Health International Medical Group Ltd.
―